Pfister, K., Friedl, T. W. P., Schäffler, H., Mergel, F., Huesmann, S., Mehmeti, F., Uhl, N., Fink, A., Braun, T., Fehm, T. N., Mueller, V., Heublein, S., Wiesmueller, L. M., Pantel, K., Rack, B., Hartkopf, A. D., Fasching, P. A., Janni, W. (2025). The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps622